243 related articles for article (PubMed ID: 23871852)
21. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Wang H; Liu Y; San Martin J
J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
[TBL] [Abstract][Full Text] [Related]
22. Quantitative CT assessment of the lumbar spine and radius in patients with osteoporosis.
Grampp S; Jergas M; Lang P; Steiner E; Fuerst T; Glüer CC; Mathur A; Genant HK
AJR Am J Roentgenol; 1996 Jul; 167(1):133-40. PubMed ID: 8659357
[TBL] [Abstract][Full Text] [Related]
23. Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group.
Bilezikian JP; Lin CJF; Brown JP; Wang AT; Yin X; Ebeling PR; Fahrleitner-Pammer A; Franek E; Gilchrist N; Miller PD; Simon JA; Valter I; Zerbini CAF; Libanati C; Chines A
Osteoporos Int; 2019 Sep; 30(9):1855-1864. PubMed ID: 31201481
[TBL] [Abstract][Full Text] [Related]
24. QCT of the femur: Comparison between QCTPro CTXA and MIAF Femur.
Wang L; Museyko O; Su Y; Brown K; Yang R; Zhang Y; Duanmu Y; Guo Z; Zhang W; Yan D; Cheng X; Engelke K
Bone; 2019 Mar; 120():262-270. PubMed ID: 30342226
[TBL] [Abstract][Full Text] [Related]
25. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
[TBL] [Abstract][Full Text] [Related]
26. Bone mineral density averaged over a region of interest on femur is affected by age-related change of bone geometry.
Luo Y
Osteoporos Int; 2018 Jun; 29(6):1419-1425. PubMed ID: 29508039
[TBL] [Abstract][Full Text] [Related]
27. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys.
Ominsky MS; Stouch B; Schroeder J; Pyrah I; Stolina M; Smith SY; Kostenuik PJ
Bone; 2011 Aug; 49(2):162-73. PubMed ID: 21497676
[TBL] [Abstract][Full Text] [Related]
28. Denosumab rapidly increases cortical bone in key locations of the femur: a 3D bone mapping study in women with osteoporosis.
Poole KE; Treece GM; Gee AH; Brown JP; McClung MR; Wang A; Libanati C
J Bone Miner Res; 2015 Jan; 30(1):46-54. PubMed ID: 25088963
[TBL] [Abstract][Full Text] [Related]
29. Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.
Lewiecki EM; Keaveny TM; Kopperdahl DL; Genant HK; Engelke K; Fuerst T; Kivitz A; Davies RY; Fitzpatrick LA
J Clin Endocrinol Metab; 2009 Jan; 94(1):171-80. PubMed ID: 18840641
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of cross-sectional and longitudinal changes in volumetric bone mineral density in postmenopausal women using single- versus dual-energy quantitative computed tomography.
Sfeir JG; Drake MT; Atkinson EJ; Achenbach SJ; Camp JJ; Tweed AJ; McCready LK; Yu L; Adkins MC; Amin S; Khosla S
Bone; 2018 Jul; 112():145-152. PubMed ID: 29704696
[TBL] [Abstract][Full Text] [Related]
31. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene.
Cosman F; Keaveny TM; Kopperdahl D; Wermers RA; Wan X; Krohn KD; Krege JH
J Bone Miner Res; 2013 Jun; 28(6):1328-36. PubMed ID: 23281041
[TBL] [Abstract][Full Text] [Related]
32. Effects of Denosumab and Teriparatide Transitions on Bone Microarchitecture and Estimated Strength: the DATA-Switch HR-pQCT study.
Tsai JN; Nishiyama KK; Lin D; Yuan A; Lee H; Bouxsein ML; Leder BZ
J Bone Miner Res; 2017 Oct; 32(10):2001-2009. PubMed ID: 28608571
[TBL] [Abstract][Full Text] [Related]
33. Effects of osteoporosis drug treatments on cortical and trabecular bone in the femur using DXA-based 3D modeling.
Winzenrieth R; Humbert L; Di Gregorio S; Bonel E; García M; Del Rio L
Osteoporos Int; 2018 Oct; 29(10):2323-2333. PubMed ID: 29974136
[TBL] [Abstract][Full Text] [Related]
34. Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.
Ganapathy A; Nieves JW; Keaveny TM; Cosman F
Bone; 2023 Feb; 167():116618. PubMed ID: 36410666
[TBL] [Abstract][Full Text] [Related]
35. Similar relationship between the time course of bone mineral density improvement and vertebral fracture risk reduction with denosumab treatment in postmenopausal osteoporosis and prostate cancer patients on androgen deprivation therapy.
Pérez Ruixo JJ; Zheng J; Mandema JW
J Clin Pharmacol; 2014 May; 54(5):503-12. PubMed ID: 24214315
[TBL] [Abstract][Full Text] [Related]
36. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis.
McClung MR; Boonen S; Törring O; Roux C; Rizzoli R; Bone HG; Benhamou CL; Lems WF; Minisola S; Halse J; Hoeck HC; Eastell R; Wang A; Siddhanti S; Cummings SR
J Bone Miner Res; 2012 Jan; 27(1):211-8. PubMed ID: 21976367
[TBL] [Abstract][Full Text] [Related]
37. Femoral strength in osteoporotic women treated with teriparatide or alendronate.
Keaveny TM; McClung MR; Wan X; Kopperdahl DL; Mitlak BH; Krohn K
Bone; 2012 Jan; 50(1):165-70. PubMed ID: 22015818
[TBL] [Abstract][Full Text] [Related]
38. Comparisons of noninvasive bone mineral measurements in assessing age-related loss, fracture discrimination, and diagnostic classification.
Grampp S; Genant HK; Mathur A; Lang P; Jergas M; Takada M; Glüer CC; Lu Y; Chavez M
J Bone Miner Res; 1997 May; 12(5):697-711. PubMed ID: 9144335
[TBL] [Abstract][Full Text] [Related]
39. Long-term effect of denosumab on bone microarchitecture as assessed by tissue thickness-adjusted trabecular bone score in postmenopausal women with osteoporosis: results from FREEDOM and its open-label extension.
Hans D; McDermott M; Huang S; Kim M; Shevroja E; McClung M
Osteoporos Int; 2023 Jun; 34(6):1075-1084. PubMed ID: 36862192
[TBL] [Abstract][Full Text] [Related]
40. The effect of the cathepsin K inhibitor ONO-5334 on trabecular and cortical bone in postmenopausal osteoporosis: the OCEAN study.
Engelke K; Nagase S; Fuerst T; Small M; Kuwayama T; Deacon S; Eastell R; Genant HK
J Bone Miner Res; 2014 Mar; 29(3):629-38. PubMed ID: 24038152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
